Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
What is Ipamorelin?
Ipamorelin is the GHRP that 'fixed' GHRPs. Earlier compounds in the class (GHRP-6, GHRP-2) worked, but they came with side effects nobody wanted — cortisol bumps, prolactin elevation, hunger like a switch had been flipped (the GHRP-6 hunger response was actually used in eating disorder research). Novo Nordisk developed ipamorelin in the late 1990s as compound NN703 — a pentapeptide engineered for selectivity. It hits the ghrelin receptor (GHSR-1a) cleanly and triggers GH release without meaningfully touching cortisol, prolactin, or your appetite system. Novo took it to Phase IIa as a GH deficiency diagnostic and then dropped it for commercial reasons, not safety. It's been a research staple ever since.
How It Works: Mechanism
Ipamorelin agonizes the ghrelin receptor (GHSR-1a) on pituitary somatotrophs, triggering pulsatile GH release. Because it doesn't touch the GHRH pathway, it pairs naturally with GHRH analogs (CJC-1295 without DAC, sermorelin) for synergistic GH release — the two pathways amplify each other through non-redundant signaling (cAMP/PKC versus PLC/IP3). The selectivity is what made it interesting in the first place: structural features of the pentapeptide make it preferentially bind GHSR-1a over related receptor subtypes, which is why you don't get the cortisol/prolactin spillover that earlier GHRPs caused.
What the Research Shows
Single-dose human studies show 3-5x peak GH elevation; IGF-1 climbs gradually over 2-4 weeks of continuous dosing. Novo's Phase IIa trial established baseline safety and tolerability. Raun et al. (1998) in the European Journal of Endocrinology is the foundational pharmacology paper if you want the receptor selectivity data in detail. There's no Phase III evidence supporting any specific indication — Novo dropped it before that. RegeneRx and others have explored applications in post-surgical recovery and muscle wasting with limited clinical traction.
Dosing and Administration
Common research protocols use 100-300 mcg per dose, 2-3 times daily subcutaneously, timed for natural GH pulse windows: pre-bed (peak GH happens within 90 minutes of sleep onset) and post-workout. Pairing with CJC-1295 without DAC at 100 mcg per dose 2-3x daily — the 'ipa + CJC' protocol — is the most common research configuration. Half-life is ~2 hours, which is why the multiple-daily-dose schedule. Eating immediately before dosing tends to blunt the GH response (especially fat or carbs); 2-3 hours fasted is the standard recommendation.
Safety Profile and Side Effects
Ipamorelin's tolerability is genuinely good. Reported side effects: injection site reactions (~10%), mild headache (5-10%), occasional transient dizziness, facial flushing when paired with GHRH analogs (more from the GHRH analog than the ipamorelin). Theoretical concern: long-term GH elevation could affect glucose metabolism and insulin sensitivity, but Novo's short-term Phase IIa didn't see meaningful impact. Receptor downregulation (desensitization) shows up after several months of continuous dosing — cycling protocols (5 days on, 2 off, or longer cycles) are standard practice in research to manage this.
Where It Fits in the Broader Research Landscape
Ipamorelin sits in the growth hormone secretagogue category. The compounds you'll see compared most often are cjc-1295, sermorelin, tesamorelin. None of them are 1:1 substitutes — each has a different mechanism profile and evidence base, and the choice usually comes down to your specific research question rather than a 'best' compound.
Practical Considerations
A few things that come up repeatedly with Ipamorelin research. First: the quality variance between suppliers is real and not subtle. Independent third-party HPLC verification on a per-batch basis (not 'representative samples') is the only thing that gets you reliable potency. Second: most research protocols start at the lower end of the dosing range and titrate up — this lets you identify individual response patterns before committing to higher exposure. Third: documentation matters more than people expect. Tracking dose, timing, injection site, and any subjective or biomarker changes is what turns 'I tried it' into actual research data.
Regulatory Reality
In the US and most jurisdictions, Ipamorelin is not approved for human use — it's sold as a research chemical or laboratory reagent. The FDA's 503A versus 503B compounding pharmacy guidelines have tightened in 2023-2024, restricting which peptides can be compounded. WADA's prohibited list also matters for athletes (some peptides are banned, some aren't — it varies). Regulatory status changes over time; check current rules before starting any research protocol.
Related Research Compounds
If you're researching Ipamorelin, the compounds you'll likely want to look at next are: CJC-1295, SERMORELIN, Tesamorelin, GHRP 2, MK-677. These appear most often in the same research contexts as alternatives or complementary compounds.
References and Regulatory Notes
This guide synthesizes published research literature on Ipamorelin. Specific citations are referenced inline where relevant. Research-compound regulatory status varies by jurisdiction; most are not approved by the FDA or equivalent agencies for human use and should be used only in research contexts compliant with applicable ethical review and regulations. This content is for research reference purposes only and does not constitute medical advice.